Pharma feed

N
Novartis AG
Endpoints News· 06 Dec 2019

With EMA review in progress, Novartis unveils more positive data on asthma therapy

Hav­ing made its mar­ket­ing pitch to the EU reg­u­la­tor, No­var­tis on Thurs­day un­veiled pos­i­tive piv­otal study da­ta sup­port­ing the use of its in­haled asth­ma treat­ment. The ther­a­py, QMF149, con­sists of the long-act­ing be­ta-ag­o­nist, or LA­BA, called in­da­caterol ac­etate and the cor­ti­cos­teroid mometa­sone furoate.

  • EMA, Inc
  • Novartis AG
  • New Offerings
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Alexion Pharmaceuticals Inc
FirstWord Pharma· 06 Dec 2019

Alexion turns down hedge fund's push for "proactive sale"

Alexion Pharmaceuticals stated Friday that its board has unanimously decided against a recommendation by hedge fund Elliott Management to immediately launch a proactive sale, saying such a move would not be in the best interest of shareholders at this time.

  • Alexion Pharmaceuticals Inc
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
Twitter· 06 Dec 2019

NEW VIDEO: Dr. David Andrews of AstraZeneca discusses the work of the Perturbation of Protein-Protein Interactions (PoPPI) program to develop computational and chemical tools to design and synthesize new small molecule drugs: https://t.co/l4wZrWNmll @AstraZeneca #drugdevelopment

Dr. David Andrews
Inhibiting protein:protein interactions: A new approach to small molecule drug discovery Dr. David Andrews, Director of the Pre-Clinical Scientific Alliance, AstraZeneca, discus...
  • SelectScience®
  • AstraZeneca PLC
  • Interactions Corporation
  • New Offerings
  • Social Updates
  • Twitter
  • Tata Consultancy Services
  • Novartis AG
  • The Hackett Group Inc
  • Events
  • Social Updates
  • Twitter
  • Johnson & Johnson
  • Partnerships and Alliances
  • Social Updates
  • Twitter
  • AstraZeneca PLC
  • Medidata Solutions
  • Awards and Recognitions
  • Social Updates
  • Twitter
  • Bristol-Myers Squibb Co
  • American Society of Hematology
  • Events
  • New Offerings
  • Social Updates
  • Twitter
National Association of Corporate Directors
Nacdonline· 06 Dec 2019

Leveraging Privacy as a Human Right to Your Company’s Advantage

Topics: Cybersecurity,Risk Management,Spotlight In 1959, Volvo introduced the auto industry’s first three-point seatbelts. In 1982, after five people in the Chicago area died from ingesting poison-laced Tylenol capsules, Johnson & Johnson pioneered the field of tamper-resistant packaging.

  • National Association of Corporate Directors
  • Johnson & Johnson
  • Volvo AG
  • Cybersecurity
  • Blogs
  • Company Websites
N
Novartis AG
Endpoints News· 06 Dec 2019

While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats

While No­var­tis is bat­tling to weak­en the chal­lengers vy­ing to mar­ket copy­cat ver­sions of its block­buster mul­ti­ple scle­ro­sis treat­ment Gilenya — the US drug reg­u­la­tor on Thurs­day ap­proved a tri­fec­ta of the drug’s first knock­offs. When they will launch is an­oth­er ques­tion al­to­geth­er.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Healio· 06 Dec 2019

FDA approves Avsola, fourth Remicade biosimilar

The FDA has approved the fourth biosimilar to infliximab, infliximab-axxq, for all eligible indications of the biologic product. Avsola (infliximab-axxq, Pfizer), a biosimilar to Remicade (infliximab, Janssen), is a tumor necrosis factor blocker intended for patients with rheumatoid arthritis, in combination with methotrexate, as well as for patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

  • Pfizer Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
  • Alexion Pharmaceuticals Inc
  • Events
  • Social Updates
  • Twitter
N
Alexion Pharmaceuticals Inc
Seeking Alpha· 06 Dec 2019

Alexion confident with current value-creating path, no sale planned

In a statement, Alexion Pharmaceuticals (NASDAQ:ALXN) says it has established a "strong foundation" to drive growth and boost shareholder value and does not plan to pursue an outright sale as proposed by shareholder Elliott Advisors.

  • Alexion Pharmaceuticals Inc
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
Amgen, Inc.
Amgen· 06 Dec 2019

FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)

THOUSAND OAKS, Calif.,Dec. 6, 2019/PRNewswire/ --Amgen(NASDAQ:AMGN) today announced that theU.S. Food and Drug Administration(FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade®(infliximab): for the treatment of moderate-to-severe rheumatoid arthritis (RA), moderate-to-severe Crohn's Disease (CD) in the adult and pediatric population, moderate-to-severe ulcerative colitis (UC) in the adult and pediatric population, chronic severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

  • Amgen, Inc.
  • Procurement and Sales
  • Regulatory and Legal
  • Press Releases
  • Company Websites
Sanofi
Sanofi· 06 Dec 2019

Sanofi Promotes Women in Tech

The most influential women in technology gathered at the Women in Technology World Series event in Amsterdam, November, to push forward ideas to transform healthcare delivery and outcomes for patients around the world. Forty delegates from Sanofi joined the discussions around ITS as a driver for digital convergence in healthcare through the implementation of disruptive technologies to create innovative solutions, add business value, and bolster competitive advantage in the marketplace.

  • Sanofi
  • Events
  • Company Websites
  • Biogen Inc
  • Events
  • Social Updates
  • Twitter
N
UCB SA
Reuters· 06 Dec 2019

Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

Dec 6 (Reuters) - UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc’s blockbuster drug, Humira, in reducing the severity of the disease. UCB’s drug, bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company.

  • UCB SA
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Novartis AG
Seeking Alpha· 06 Dec 2019

Novartis developing 25+ blockbusters - R&D Day

At its R&D Day in London yesterday, Novartis (NYSE:NVS) detailed its development efforts. Key points: 25+ potential blockbusters in development, 16 advanced platform therapies and 160+ projects in the clinic (500+ clinical trials). 80+ regulatory submissions expected 2020 - 2022.

  • Novartis AG
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
Novartis AG
FierceBiotech· 06 Dec 2019

Novartis posts more phase 3 data as EMA reviews asthma combo

Novartis’ asthma combo already beat an inhaled corticosteroid at improving lung function, meeting the primary endpoint in a phase 3 study. Now, the Big Pharma is unveiling yet more data showing how the treatment fared against the standard of care: a combination of the same types of drugs.

  • EMA, Inc
  • Novartis AG
  • New Offerings
  • Regulatory and Legal
  • Press Releases
  • News and Other Websites
N
Novartis AG
Seeking Alpha· 06 Dec 2019

Dr. Reddy's launches Deferasirox oral suspension and film-coated tablets in U.S.

Dr. Reddy’s Laboratories (NYSE:RDY) has launched Deferasirox Tablets for Oral Suspension and Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Novartis Pharma AG's Exjade (deferasirox) Tablets for Oral Suspension and Jadenu (deferasirox) Film-Coated Tablets 90, 180 and 360 mg, respectively.

  • Novartis AG
  • New Offerings
  • News Articles
  • News and Other Websites
N
Novartis AG
Pharmaphorum· 06 Dec 2019

Novartis pulls rival to Roche’s risdiplam in SMA, says market limited -

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a different take. At its R&D day yesterday, Bradner said that Novartis has decided to suspend development of its rival drug LMI070 – also known as branaplam – in SMA as “we don’t see a big opportunity for oral therapy” in the muscle-wasting disease.

  • Roche Products Ltd
  • Novartis AG
  • Competitive Landscape
  • News Articles
  • News and Other Websites
N
Amgen, Inc.
Pharmaphorum· 06 Dec 2019

Amgen strikes outcomes-based payment plan for Enbrel with Abarca -

Pharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases drug that will see rebates issued should patients stop using the drug. There are two cheaper biosimilars approved and ready to launch in the US for Enbrel but Amgen’s legal defences are preventing them from making it to the market.

  • Amgen, Inc.
  • New Offerings
  • News Articles
  • News and Other Websites
N
Island Pacific
Brochherald· 06 Dec 2019

South Texas Money Management LTD Has Lowered Amgen (AMGN) Position by $1.26 Million; Connor Clark & Lunn Investment Management LTD Raised Prudential Plc Adr (PUK) Holding

Connor Clark & Lunn Investment Management Ltd increased its stake in Prudential Plc Adr (PUK) by 137.52% based on its latest 2019Q3 regulatory filing with the SEC. Connor Clark & Lunn Investment Management Ltd bought 117,375 shares as the company’s stock declined 8.39% .

  • Island Pacific
  • Prudential PLC
  • Amgen, Inc.
  • South Texas Money Management
  • M&A Activities
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Boehringer Ingelheim GmbH
Abril· 06 Dec 2019

Boehringer faz recall de medicamento para pressão alta

O Procon-SP informou na última quinta-feira que a empresa Boehringer Ingelheim do Brasil vai iniciar o recall do lote B22849 do medicamento Cardizem CD 180 mg (cloridrato de diltiazem), usado para controle da pressão arterial. De acordo com a companhia, o motivo do recall está relacionado a “algumas cápsulas abaixo do peso normal, com menor quantidade do ingrediente ativo”.

  • Boehringer Ingelheim GmbH
  • Controle
  • Operational Challenges
  • News Articles
  • News and Other Websites
N
Novartis AG
FiercePharma· 06 Dec 2019

FDA greenlights generics of Novartis' $3B MS star Gilenya amid legal fight

In June, a U.S. district court judge temporarily shielded Novartis’ $3 billion-a-year multiple sclerosis (MS) drug Gilenya from generic competition—but that’s not preventing generics makers from lining up at the starting gate. Thursday, the FDA approved the first three generic versions of Gilenya, which will be made by HEC Pharm, Biocon and Sun Pharmaceutical.

  • Novartis AG
  • Regulatory and Legal
  • Press Releases
  • News and Other Websites
Novartis AG
Express Pharma· 06 Dec 2019

US FDA approves generic versions of Novartis blockbuster MS treatment

The US Food and Drug Administration approved three generic versions of Swiss drugmaker Novartis AG’s top-selling multiple sclerosis (MS) medicine Gilenya. The approval allows HEC Pharm Co, Biocon and Sun Pharmaceutical Industries to produce the drug for the treatment of relapsing forms of MS in adult patients.

  • Novartis AG
  • Regulatory and Legal
  • Company Websites
1 2 3 4 5